Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Fresenius Kabi And Dr. Reddy's Announce FDA Approval Of Rituximab Biosimilar

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mondaq.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Fresenius Kabi and Dr. Reddy's Laboratories have received FDA approval for their rituximab biosimilar, adding to several already approved alternatives to Genentech's RITUXAN in the U.S. market.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 1 Aug 2026 and 14 Aug 2026.

◆ ◆ The Wire takeaway

You face growing competition in the biosimilar monoclonal antibody market as more FDA-approved alternatives to Rituxan enter the U.S. This approval opens up new commercial opportunities but also pressures you to accelerate market access and differentiation.

◆ Coverage

5 sources · first reported 1 Aug 2026 · latest 14 Aug 2026

◆ Related on Wire

◆ Topics

BiotechbiosimilarsFDA-approvalrituximabBiotechUS-market